Translational Development Acquisition (TDAC) Common Equity (2023 - 2026)

Translational Development Acquisition has reported Common Equity for 4 years, with the latest figure at -$6.8 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 14.77% year-over-year to -$6.8 million; the trailing twelve-month figure through Mar 2026 stood at -$6.8 million (down 14.77% YoY), and the FY2025 full-year result was -$6.5 million, down 16.87% from the prior year.
• Common Equity for Q1 2026 stood at -$6.8 million, down from -$6.5 million in the prior quarter.
• The five-year high for Common Equity was -$507658.0 in Q4 2023, with the low at -$6.8 million in Q1 2026.
• Historically, Common Equity has averaged -$4.3 million across 4 years, with a median of -$5.9 million in 2025.
• Annual changes were most pronounced in 2025 — Common Equity slumped 1110.6% — and 2026, when it dropped 14.77%.
• Translational Development Acquisition's Common Equity stood at -$507658.0 in 2023, then slumped by 1002.63% to -$5.6 million in 2024, then retreated by 16.87% to -$6.5 million in 2025, then declined by 4.3% to -$6.8 million in 2026.
• The last three Common Equity figures came in at -$6.8 million (Q1 2026), -$6.5 million (Q4 2025), and -$6.4 million (Q3 2025), per Business Quant data.